RayzeBio Announces Closing of Upsized $358 Million IPO

SAN DIEGO–(BUSINESS WIRE)–Sep. 19, 2023– RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 2,591,640 additional shares from […]